Publications in collaboration with researchers from Hospital Universitario La Fe (21)

2023

  1. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  2. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2749-2758

2022

  1. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  2. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

  3. Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study

    European Thyroid Journal, Vol. 11, Núm. 5

2021

  1. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

2019

  1. Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years

    Leukemia and Lymphoma

  2. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580

  3. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

    Hematological Oncology, Vol. 37, Núm. 2, pp. 143-150

  4. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

    PLoS ONE, Vol. 14, Núm. 2

2018

  1. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

  2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

2017

  1. Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 17, Núm. 3, pp. 186-191

  2. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group

    Cancer, Vol. 123, Núm. 19, pp. 3709-3716

2015

  1. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1005-1013

  2. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1014-1019

2014

  1. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: A multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

    Leukemia and Lymphoma, Vol. 55, Núm. 1, pp. 51-55

  2. High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma

    Leukemia and Lymphoma

  3. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

    Haematologica

2013

  1. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study

    BMC Cancer, Vol. 13